ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,157,823 | -96.9% | 57,718 | -95.6% | 0.00% | -100.0% |
Q2 2023 | $37,277,681 | +68.0% | 1,321,435 | +2.4% | 0.02% | +50.0% |
Q1 2023 | $22,193,091 | -19.3% | 1,290,296 | -5.5% | 0.01% | -16.7% |
Q4 2022 | $27,501,130 | -4.7% | 1,365,498 | +2.5% | 0.01% | -14.3% |
Q3 2022 | $28,849,000 | -24.2% | 1,331,884 | -1.7% | 0.01% | -17.6% |
Q2 2022 | $38,060,000 | -17.2% | 1,354,463 | +35.9% | 0.02% | -5.6% |
Q1 2022 | $45,990,000 | -41.0% | 996,759 | +7.5% | 0.02% | -35.7% |
Q4 2021 | $77,918,000 | +18.6% | 926,937 | -6.0% | 0.03% | +7.7% |
Q3 2021 | $65,704,000 | +31.3% | 985,953 | +4.8% | 0.03% | +30.0% |
Q2 2021 | $50,052,000 | +4.4% | 940,828 | -14.9% | 0.02% | -4.8% |
Q1 2021 | $47,958,000 | +10.7% | 1,105,282 | +32.5% | 0.02% | +5.0% |
Q4 2020 | $43,341,000 | +72.0% | 834,448 | +8.3% | 0.02% | +42.9% |
Q3 2020 | $25,196,000 | +5.3% | 770,770 | +54.7% | 0.01% | 0.0% |
Q2 2020 | $23,927,000 | – | 498,272 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Mayo Clinic | 362,459 | $15,727,096,000 | 18.11% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,664,409 | $115,609,000 | 2.54% |
Matrix Capital Management Company, LP | 3,821,739 | $165,825,000 | 1.92% |
Avidity Partners Management LP | 1,263,300 | $54,815,000 | 1.51% |
Redmile Group, LLC | 2,221,044 | $96,371,000 | 1.36% |
Affinity Asset Advisors, LLC | 77,500 | $3,363,000 | 1.14% |
SPHERA FUNDS MANAGEMENT LTD. | 175,140 | $7,599,000 | 0.58% |
Eventide Asset Management | 832,000 | $36,100,000 | 0.54% |
Integral Health Asset Management, LLC | 40,000 | $1,736,000 | 0.50% |
VIKING GLOBAL INVESTORS LP | 2,399,284 | $104,105,000 | 0.31% |